Oncology

Cancer cells cunningly evade the immune system using many different mechanisms. We believe that only when the full potential of the human immune system is unleashed, tumors can be effectively treated or even cured. One of our therapeutic approaches is to boost both the innate and adaptive immunity with monoclonal antibodies (mAbs) and bispecific antibodies. We are also interrogating non-immune pathways that may play key roles in the tumor microenvironment for their potential in developing novel therapeutics.

 

Clinical Trials

• Mavrostobart (PT199) is in a Phase 1/2 clinical trial for NSCLC and PDAC (the MORNINGSTAR study; ClinicalTrials.gov ID: NCT05431270).
• Spevatamig (PT886) is in a Phase 1/2 clinical trial for metastatic/advanced gastric, gastroesophageal junction and pancreatic adenocarcinoma (the TWINPEAK study; ClinicalTrials.gov ID: NCT05482893).
• Peluntamig (PT217) is in a Phase 1/2 clinical trial for advanced refractory cancers expressing DLL3 (the SKYBRIDGE study; ClinicalTrials.gov ID: NCT05652686).

 

Publications

April 20^th, 2026, AACR:

Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibody

Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept study

Pharmacokinetics of spevatamig (PT886), a bispecific antibody targeting CLDN18.2 and CD47, in patients with advanced gastrointestinal cancers as monotherapy or combination therapy

January 9^th, 2026, ASCO-GI:

Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC); TWINPEAK Study

 

Expanded Access Policy

Read more about the Expanded Access Policy.